Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa single ascending dose safety, tolerability and pharmacokinetic study of NicaPlant in aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping
2016-004521-17Phase 2Completed
- Sponsor
- BIT Pharma
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nicardipine in subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH), sponsored by BIT Pharma. Primary endpoint: Safety and tolerability of NicaPlant single ascending doses. Started Dec 2017; status: completed.
02
Drugs
nicardipine
03
Conditions
subarachnoid hemorrhage (SAH)intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on 2016-004521-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004521-17.